Table 1.
Peptide | Antimicrobial Activity (MIC; µM) | Cytotoxic Activity (IC50; μM) | |||||
---|---|---|---|---|---|---|---|
C. g. | B. s. | S. a. | E. c. | P. a. | A2058 | MRC-5 | |
Turgencin AMox1 (72% Mox1, 28% Mox0) |
0.4 | 0.4 | 6.3 | 0.8 | 1.6 | 1.4 | 4.8 |
Turgencin B (67% Mox0, 29% Mox1, 4% Mox2) |
1.6 | 1.6 | >100.0 | 12.5 | 25.0 | 4.1 | 7.5 |
Turgencin BMox1 (88% Mox1, 10% Mox2, 2% Mox0) |
1.6 | 3.1 | >100.0 | 25.0 | >100.0 | 27.4 | >50.0 |
Turgencin BMox2 (97% Mox2, 3% Mox1) |
25.0 | 25.0 | >100.0 | >100.0 | >100.0 | >50.0 | >50.0 |
C.g.—Corynebacterium glutamicum, B.s.—Bacillus subtilis, S.a.—Staphylococcus aureus, E.c.—Escherichia coli, P.a.—Pseudomonas aeruginosa, A2058—Human melanoma cancer cell line and MRC-5—Non-malignant human fibroblast cell line.